What's on this Page
What is Botulism Immune Globulin BIG IV
Botulism Immune Globulin BIG IV is an intravenous solution of purified human immunoglobulin G (IgG), with trace amounts of IgA and IgM. The product is derived from pooled adult plasma from persons immunized with pentavalent botulinium toxoid.
Donors for BIG-IV are selected based on high titers of neutralizing antibody against botulinum neurotoxins type A and B. All donors for the product are tested and found negative for antibodies against HIV, HBV, and HCV.
Botulism immune globulin is used to treat infant botulism caused by toxin type A or B.
Clinical studies show that BIG-IV reduces the overall hospital stay for infants as well as the time spent in the ICU, on mechanical ventilation, and on tube-feedings.
The FDA approved Botulism Immune Globulin BIG IV (BabyBIG®) in October 2003.
Indications
- botulism
For the treatment of infant botulism caused by botulinum toxin type A or type B
Side Effects
- anaphylactic shock
- anaphylactoid reactions
- angioedema
- anuria
- aseptic meningitis
- azotemia
- back pain
- chills
- fever
- myalgia
- nausea
- oliguria
- osmotic nephrosis
- rash
- renal failure (unspecified)
- renal tubular necrosis
- vomiting
- wheezing
Monitoring Parameters
- serum creatinine/BUN
Contraindications
- breast-feeding
- cardiac disease
- children
- coagulopathy
- coronary artery disease
- dehydration
- diabetes mellitus
- geriatric
- heart failure
- hemolysis
- hemolytic anemia
- hypertriglyceridemia
- hyponatremia
- hypovolemia
- IgA deficiency
- infection
- infusion-related reactions
- intramuscular administration
- pregnancy
- renal disease
- renal failure
- renal impairment
- sepsis
- thromboembolic disease
- vaccination
- viral infection
Interactions
No information is available regarding drug interactions associated with Botulism Immune Globulin BIG IV